• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    10/2/23 1:35:22 PM ET
    $ACAD
    $BGNE
    $ICPT
    $IMCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACAD alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    ACAD CALL TRADE BULLISH 11/17/23 $25.00 $195.0K 298 3.0K
    TEVA CALL SWEEP BEARISH 12/15/23 $10.00 $52.0K 60.2K 2.8K
    ICPT CALL SWEEP BULLISH 12/15/23 $15.00 $39.0K 929 300
    IMCR PUT SWEEP BEARISH 10/20/23 $55.00 $56.7K 250 122
    PTCT CALL SWEEP BULLISH 03/15/24 $21.00 $30.4K 0 102
    LNTH CALL SWEEP BULLISH 11/17/23 $65.00 $58.6K 9 92
    OGN CALL TRADE BULLISH 01/16/26 $10.00 $36.0K 100 50
    MRK PUT TRADE BEARISH 01/19/24 $110.00 $27.7K 4.9K 30
    REGN PUT SWEEP BULLISH 01/17/25 $800.00 $146.6K 159 22
    BGNE PUT TRADE BEARISH 11/17/23 $250.00 $43.5K 6 6

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • Regarding ACAD (NASDAQ:ACAD), we observe a call option trade with bullish sentiment. It expires in 46 day(s) on November 17, 2023. Parties traded 3000 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $195.0K, with a price of $65.0 per contract. There were 298 open contracts at this strike prior to today, and today 3010 contract(s) were bought and sold.

    • For TEVA (NYSE:TEVA), we notice a call option sweep that happens to be bearish, expiring in 74 day(s) on December 15, 2023. This event was a transfer of 707 contract(s) at a $10.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $52.0K, with a price of $73.0 per contract. There were 60292 open contracts at this strike prior to today, and today 2851 contract(s) were bought and sold.

    • Regarding ICPT (NASDAQ:ICPT), we observe a call option sweep with bullish sentiment. It expires in 74 day(s) on December 15, 2023. Parties traded 100 contract(s) at a $15.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $39.0K, with a price of $390.0 per contract. There were 929 open contracts at this strike prior to today, and today 300 contract(s) were bought and sold.

    • Regarding IMCR (NASDAQ:IMCR), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on October 20, 2023. Parties traded 73 contract(s) at a $55.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $56.7K, with a price of $770.0 per contract. There were 250 open contracts at this strike prior to today, and today 122 contract(s) were bought and sold.

    • Regarding PTCT (NASDAQ:PTCT), we observe a call option sweep with bullish sentiment. It expires in 165 day(s) on March 15, 2024. Parties traded 72 contract(s) at a $21.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $30.4K, with a price of $424.0 per contract. There were 0 open contracts at this strike prior to today, and today 102 contract(s) were bought and sold.

    • For LNTH (NASDAQ:LNTH), we notice a call option sweep that happens to be bullish, expiring in 46 day(s) on November 17, 2023. This event was a transfer of 85 contract(s) at a $65.00 strike. This particular call needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $58.6K, with a price of $690.0 per contract. There were 9 open contracts at this strike prior to today, and today 92 contract(s) were bought and sold.

    • Regarding OGN (NYSE:OGN), we observe a call option trade with bullish sentiment. It expires in 837 day(s) on January 16, 2026. Parties traded 50 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $720.0 per contract. There were 100 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold.

    • For MRK (NYSE:MRK), we notice a put option trade that happens to be bearish, expiring in 109 day(s) on January 19, 2024. This event was a transfer of 30 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $27.7K, with a price of $925.0 per contract. There were 4921 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold.

    • For REGN (NASDAQ:REGN), we notice a put option sweep that happens to be bullish, expiring in 473 day(s) on January 17, 2025. This event was a transfer of 18 contract(s) at a $800.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $146.6K, with a price of $8163.0 per contract. There were 159 open contracts at this strike prior to today, and today 22 contract(s) were bought and sold.

    • For BGNE (NASDAQ:BGNE), we notice a put option trade that happens to be bearish, expiring in 46 day(s) on November 17, 2023. This event was a transfer of 6 contract(s) at a $250.00 strike. The total cost received by the writing party (or parties) was $43.5K, with a price of $7250.0 per contract. There were 6 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $BGNE
    $ICPT
    $IMCR

    CompanyDatePrice TargetRatingAnalyst
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/23/2026$35.00Neutral → Outperform
    Mizuho
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    PTC Therapeutics Inc.
    $PTCT
    1/28/2026$119.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    1/8/2026$135.00Peer Perform → Outperform
    Wolfe Research
    Regeneron Pharmaceuticals Inc.
    $REGN
    1/7/2026$860.00Underperform → Buy
    BofA Securities
    Immunocore Holdings plc
    $IMCR
    1/7/2026$55.00Sell → Buy
    UBS
    Merck & Company Inc.
    $MRK
    12/18/2025$130.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $ACAD
    $BGNE
    $ICPT
    $IMCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ACADIA Pharmaceuticals upgraded by Mizuho with a new price target

    Mizuho upgraded ACADIA Pharmaceuticals from Neutral to Outperform and set a new price target of $35.00

    2/23/26 8:28:41 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Merck with a new price target

    Barclays initiated coverage of Merck with a rating of Overweight and set a new price target of $140.00

    2/20/26 8:25:04 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Merck from Hold to Buy and set a new price target of $150.00

    2/13/26 8:35:09 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BGNE
    $ICPT
    $IMCR
    SEC Filings

    View All

    Organon & Co. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Organon & Co. (0001821825) (Filer)

    2/20/26 7:30:42 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by PTC Therapeutics Inc.

    10-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    2/19/26 4:36:19 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    2/19/26 4:14:13 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BGNE
    $ICPT
    $IMCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF BUSINESS OFFICER Pauwels Eric sold $209,398 worth of shares (3,019 units at $69.36), decreasing direct ownership by 4% to 77,122 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    2/20/26 5:20:11 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $511,253 worth of shares (7,371 units at $69.36), decreasing direct ownership by 2% to 387,082 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    2/20/26 5:20:09 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, CHIEF ACCOUNTING OFFICER Utter Christine Marie sold $172,984 worth of shares (2,494 units at $69.36), decreasing direct ownership by 3% to 70,199 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    2/20/26 5:20:14 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BGNE
    $ICPT
    $IMCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PTC Therapeutics to Participate at Upcoming Investor Conferences

    WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conference 2026Monday, March 2 at 9:50 a.m. ETLeerink 2026 Global Healthcare ConferenceTuesday, March 10 at 4:20 p.m. ETBarclays Global Healthcare Conference 2026Wednesday, March 11 at 8 a.m. ETThe presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived f

    2/23/26 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device

    MIUDELLA® is a strategic addition to Organon's portfolio, strengthening its long‑term commitment to advancing women's health Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA's alternate supply chain entities and certain other conditions.

    2/23/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BGNE
    $ICPT
    $IMCR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BGNE
    $ICPT
    $IMCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chair Cox Carrie Smith bought $501,755 worth of shares (65,400 units at $7.67) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    11/13/25 4:05:10 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    9/9/25 4:02:56 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cox Carrie Smith bought $100,591 worth of shares (12,469 units at $8.07) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/15/25 4:09:09 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BGNE
    $ICPT
    $IMCR
    Leadership Updates

    Live Leadership Updates

    View All

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600

    NEW YORK, Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600:  S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace The Interpublic Group of Companies Inc. (NYSE:IPG) in the S&P 500, and PTC Therapeutics Inc. (NASD: PTCT) will replace Sandisk in the S&P SmallCap 600 effective prior to the opening of trading on Friday, November 28. S&P 500 constituent Omnicom Group Inc. (NYSE:OMC) is acquiring The Interpublic Group of Companies in a deal expected to close soon, pending final conditions.Upwork Inc. (NASD: UPWK) will replace Premier Inc. (NASD: PINC) in the S&P SmallCap 600 effective prior to the open of trading

    11/24/25 6:01:00 PM ET
    $FIBK
    $GIL
    $HBI
    Major Banks
    Finance
    Apparel
    Consumer Discretionary

    $ACAD
    $BGNE
    $ICPT
    $IMCR
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    – Full-year 2025 product and royalty revenue of $831M, exceeding guidance –– Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively –– Cash of $1.95B as of December 31, 2025 –WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.  "We delivered another strong quarter and finish to 2025, building on the successful global launch of Sephience," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "With our robust commercial engine, innovative R&D programs,

    2/19/26 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025

    Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Wednesday, February 25, 2026. Following the announcement, the Company will host a live teleconference and webcast a

    2/18/26 7:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 26, 2026, to discuss its financial and operating results for the fourth quarter and full year of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    2/12/26 8:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACAD
    $BGNE
    $ICPT
    $IMCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

    12/10/24 9:30:34 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

    12/4/24 4:05:33 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 8:21:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care